Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia

  title={Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia},
  author={R. Miles and Staci D. Arnold and M. Cairo},
  journal={British Journal of Haematology},
  • R. Miles, Staci D. Arnold, M. Cairo
  • Published 2012
  • Medicine
  • British Journal of Haematology
  • Burkitt lymphoma/leukaemia is the most common (40%) form of non‐Hodgkin lymphoma that occurs in children and adolescents. The prognosis of advanced (disseminated) Burkitt lymphoma/leukaemia in children and adolescents three decades ago had a 5‐year event‐free survival (EFS) of <40%, and required combination chemotherapy and radiation therapy over a 1–2 year period. Currently, the prognosis for the same advanced stage has a 5‐year EFS of 85–90% with <6 months of chemotherapy only. Radiation… CONTINUE READING
    67 Citations

    Paper Mentions

    Interventional Clinical Trial
    The purpose of this study is to test whether adding 4 injections of rituximab and increasing the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with… Expand
    ConditionsMature B-cell Non-Hodgkin Lymphoma
    Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma.
    • 16
    Silent presentation of multiple metastasis Burkitt lymphoma in a child
    • 1
    Mature B-Cell Lymphoma and Leukemia in Children and Adolescents—Review of Standard Chemotherapy Regimen and Perspectives
    • 21
    Outcome of Early Stage Pediatric Non-Lymphoblastic Non-Hodgkin Lymphoma
    • 1
    Adolescent and young adult non‐Hodgkin lymphoma
    • 16
    Rituximab in the treatment of childhood mature B‐cell lymphoma: “Where do we go from here”
    • M. Cairo
    • Medicine
    • British journal of haematology
    • 2019
    • 2
    A step towards the cure of Burkitt's lymphoma in developing countries
    • C. Klumb
    • Medicine
    • Revista brasileira de hematologia e hemoterapia
    • 2012
    • 1
    • PDF


    Adolescent non‐Hodgkin lymphoma and Hodgkin lymphoma: state of the science
    • 95
    Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group.
    • 146
    Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
    • 138